Clozapine

Active ingredient: Clozapine

In short: Clozapine tablets are indicated for the treatment of severely ill patients with schizophrenia who fail to respond adequately to standard antipsychotic treatment. Because of the risks of severe neutropenia and of seizure associated with its use, clozapine tablets should be used only in patients who h

Forms & strengthsClozapine Tablets USP, 50 mgare pale yellow colored, round, flat faced, bevel edged uncoated tablets debossed with ‘C facilitated scoreline (functional) C’ on one side and ‘55’ on the other side.
LabelRemedyrepack Inc.
Label updatedNov 16, 2026

What is Clozapine used for?

Clozapine tablets are indicated for the treatment of severely ill patients with schizophrenia who fail to respond adequately to standard antipsychotic treatment. Because of the risks of severe neutropenia and of seizure associated with its use, clozapine tablets should be used only in patients who have failed to respond adequately to standard antipsychotic treatment

.

The effectiveness of clozapine tablets in treatment-resistant schizophrenia was demonstrated in a 6-week, randomized, double-blind, active-controlled study comparing clozapine tablets and chlorpromazine in patients who had failed other antipsychotics

.

Clozapine tablets are indicated for reducing the risk of recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder who are judged to be at chronic risk for re-experiencing suicidal behavior, based on history and recent clinical state. Suicidal behavior refers to actions by a patient that put him/herself at risk for death.

The effectiveness of clozapine tablets in reducing the risk of recurrent suicidal behavior was demonstrated over a two-year treatment period in the InterSePTâ„¢ trial

.

âš  Boxed warning (FDA's strongest warning)

Severe Neutropenia

Clozapine

has caused severe neutropenia which is associated with an increased risk of serious and potentially fatal infections. Prior to initiating

clozapine

treatment, obtain baseline ANC(s).

Clozapine

initiation is not recommended in patients with a baseline ANC less than 1500/μL (less than 1000/μL for those with Benign Ethnic Neutropenia (also knownasDuffy-null associated neutrophil count)). See recommendations for dosage modifications based on ANC levels during

clozapine

treatment

.

Consider a hematology consultation before initiating

clozapine

or during

clozapine

treatment

.

Orthostatic Hypotension, Bradycardia, Syncope

Orthostatic hypotension, bradycardia, syncope, and cardiac arrest have occurred with

clozapine

treatment. The risk is highest during the initial titration period, particularly with rapid dose escalation. These reactions can occur with the first dose, with doses as low as 12.5 mg per day

, or when restarting patients who have had even a brief interruption in treatment with clozapine. Initiate treatment at 12.5 mg once or twice daily; titrate slowly; and use divided dosages

to minimize risk. Use

clozapine

cautiously in patients with cardiovascular or cerebrovascular disease or conditions predisposing to hypotension (e.g., dehydration, use of antihypertensive medications)

.

Seizures

Seizures have occurred with

clozapine

treatment. The risk is dose-related. Initiate treatment at 12.5 mg, titrate gradually, and use divided dosing. …

Clozapine dosage

Prior to initiating clozapine tablets treatment, obtainabaseline absolute neutrophil count (ANC). Clozapine tablets initiation is not recommended in patients with an ANC less than 1500/μL

.

For patients with documented Benign Ethnic Neutropenia (BEN) (also known as Duffy-null associated neutrophil count), obtain at least two baseline ANC levels. Clozapine tablets initiation is not recommendedinpatients with BEN with an ANC less than 1000/μL

.

For dosage modifications basedonANC results,

see

Dosage and Administration (2.3,

2.4)

.

To reduce the risk of orthostatic hypotension, bradycardia, and syncope,therecommended starting dosage is much lower than the target dosage

.

Clozapine tablets can be taken with or without food

. The recommended starting oral dosage of clozapine tablets is 12.5 mg once or twice daily. If well-tolerated, increase the total daily dose in increments of 25 mg to 50 mg per day to achieve a target dosage of 150 mg to 225 mg twice per day by the endoftwo weeks. Subsequently, may increase the dosage in increments of up to 100 mg once weekly or twice weekly. The maximum recommended clozapine tablets oral dosage is 450 mg twice daily.

Table 1 provides recommended clozapine tablets dosage modifications based on ANC results

.

For dosage modifications basedonANC results for patients with Benign Ethnic Neutropenia (BEN) (also known as Duffy-null associated neutrophil count), see Table 2

.

1Confirm all initial reports of ANC less than 1500/μL with a repeat ANC measurement within 24 hours

Recommended Dosage

Modification | Recommended Frequency of ANC Testing During Clozapine Tablets Treatment

ANC Within Normal Range (≥ 1500/μL)

No dosage modification;

continue treatment | Day 1 to Month 6: Weekly

Month 7 to Month 12: Every 2 weeks

Month 13 and thereafter: Every month

If clozapine tablets treatment is reinitiated after a dosage interruption (e.g., patient had neutropenia which required dosage interruption and now has a normal ANC level) for:

< 30 days, continue the previous ANC testing frequency

≥ 30 days, obtain ANC tests according to the frequency for patients who initiate treatment

Mild Neutropenia (ANC between 1000 to 1499/μL)

1

No dosage modification;

continue treatment | Three times weekly

Once ANC ≥ 1500/μL, recommend returning to the patient’s last

Normal RangeANC testing frequency

Moderate Neutropenia (ANC between 500 to 999/μL)

1

Interrupt treatment and recommend hematology consultation

Resume treatment once ANC ≥1000/μL | Daily

Once ANC ≥ 1000/μL, three times weekly

Once ANC ≥ 1500/μL, test weekly for 4 weeks. …

How to take Clozapine — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (

Medication Guide). Discuss the following issues with patients and caregivers:

Severe Neutropenia:

Instruct patients (and caregivers)

:

- About the risk of developing severe neutropenia and infection with clozapine tablets treatment.

- Instruct patients to immediately report to their health care provider any symptom or sign of during clozapine tablets treatment.

- About the importance of having frequent ANC testing.

Orthostatic Hypotension, Bradycardia, and Syncope

: Inform patients and caregivers about the risk of orthostatic hypotension and syncope, especially during the period of initial dose titration. Instruct them to strictly follow the clinician’s instructions for dosage and administration

.

Advise patients to consult their clinician immediately if they feel faint, lose consciousness or have signs or symptoms suggestive of bradycardia or arrhythmia

[

Warnings and Precautions (5.2)].

Seizures:

Inform patients and caregivers about the significant risk of seizure during clozapine treatment. Caution them about driving and any other potentially hazardous activity while taking clozapine tablets

. …

Warnings & precautions

Do not take this medicine if: Clozapine tablets are contraindicated in patients with a history of hypersensitivity to clozapine (e.g., photosensitivity, vasculitis, erythema multiforme, or Stevens-Johnson syndrome) or any other component of clozapine tablets

.

Clozapine has caused severe neutropenia (absolute neutrophil count (ANC) less than 500/μL)

and is associated with an increased risk of serious and potentially fatal infections. Severe neutropenia occurred inasmall percentage of clozapine-treated patients. The risk of severe neutropenia appears greatest during the first 18 weeks of clozapine treatment. The mechanism by which clozapine causes neutropenia is unknown. Neutropenia is not dose dependent.

Consider a hematology consultation before initiating clozapine treatmentorduring treatment.

ANC MonitoringandDosage Modifications

Prior to initiating clozapine treatment, obtain a baseline ANC. Clozapine initiation is not recommended in patients with a baseline ANC less than 1500/μL. Throughout clozapine treatment, regularly monitor ANC. Table1 provides recommendations for dosage modifications (dosage interruption and treatment discontinuation), based on ANC levels, during clozapine treatment and frequency of ANC monitoring

.

ANC Monitoring and Dosage ModificationinPatients with Benign Ethnic Neutropenia

Patients with Benign Ethnic Neutropenia (BEN) (also known as Duffy-null associated neutrophil count) generally have lower baseline neutrophil counts but they are not at higher risk for developing infections, and they are notatincreased risk for developing clozapine-induced neutropenia.

For patients with documented BEN, obtain at least two baseline ANC levels prior to clozapine initiation. Clozapine initiation is not recommended in patients with BEN with an ANC less than 1000/μL. …

Clozapine side effects

The following adverse reactions are discussed in more detail in other sections of the labeling:

Severe Neutropenia

Orthostatic Hypotension, Bradycardia, and Syncope

Falls

Seizures

Myocarditis, Pericarditis, Cardiomyopathy, and Mitral Valve Incompetence

Increased Mortality in Elderly Patients with Dementia-Related Psychosis

Gastrointestinal Hypomotility with Severe Complications

Eosinophilia

QT Interval Prolongation

Metabolic Changes (Hyperglycemia and Diabetes Mellitus, Dyslipidemia, and Weight Gain)

Neuroleptic Malignant Syndrome

Hepatotoxicity

Fever

Pulmonary Embolism

Anticholinergic Toxicity

Interference with Cognitive and Motor Performance

Tardive Dyskinesia

Cerebrovascular Adverse Reactions

Recurrence of Psychosis and Cholinergic Rebound after Abrupt Discontinuation

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

The most commonly reported adverse reactions (≥5%) across clozapine clinical trials were: CNS reactions, including sedation, dizziness/vertigo, headache, and tremor; cardiovascular reactions, including tachycardia, hypotension, and syncope; autonomic nervous system reactions, including hypersalivation, sweating, dry mouth, and visual disturbances; gastrointestinal reactions, including constipation and nausea; and fever. …

Drug interactions

Clozapine is a substrate for many cytochrome P450 isozymes, in particular CYP1A2, CYP3A4, and CYP2D6. Use caution when administering clozapine concomitantly with drugs that are inducers or inhibitors of these enzymes.

CYP1A2

Inhibitors

Concomitant use of clozapine and CYP1A2 inhibitors can increase plasma levels of clozapine, potentially resulting in adverse reactions. Reduce the clozapine dose to one-third of the original dose when clozapine is coadministered with strong CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin, or enoxacin). The clozapine dose should be increased to the original dose when coadministration of strong CYP1A2 inhibitors is discontinued

.

Moderate or weak CYP1A2 inhibitors include oral contraceptives and caffeine. Monitor patients closely when clozapine is coadministered with these inhibitors. Consider reducing the clozapine dosage if necessary

.

CYP2D6 and CYP3A4 Inhibitors

Concomitant treatment with clozapine and CYP2D6 or CYP3A4 inhibitors (e.g., cimetidine, escitalopram, erythromycin, paroxetine, bupropion, fluoxetine, quinidine, duloxetine, terbinafine, or sertraline) can increase clozapine levels and lead to adverse reactions

. Use caution and monitor patients closely when using such inhibitors. Consider reducing the clozapine dose

. …

About this medicine

Clozapine, an atypical antipsychotic drug, is a tricyclic dibenzodiazepine derivative, 8-chloro-11-(4-methyl-1-piperazinyl)-5

H-dibenzo [

b,e] [1,4] diazepine. The structural formula is:

Clozapine USP is available in pale yellow colored tablets of 25 mg, 50 mg, 100 mg, and 200 mg for oral administration.

Active Ingredient: clozapine

Inactive Ingredients are colloidal silicon dioxide, corn starch, lactose monohydrate, magnesium stearate, povidone, and talc.

How it works: The mechanism of action of clozapine is unknown. However, it has been proposed that the therapeutic efficacy of clozapine in schizophrenia is mediated through antagonism of the dopamine type 2 (D 2) and the serotonin type 2A (5-HT 2A) receptors. Clozapine also acts as an antagonist at adrenergic, cholinergic, histaminergic and other dopaminergic and serotonergic receptors.

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 849a3649-b7f5-4c07-be13-c6072c16044e. Read the full official label on DailyMed.

Related medicines

Sertraline Escitalopram Bupropion Fluoxetine Trazodone Duloxetine Prednisone Buspirone